Keywords: RIPTAC, induced proximity, bifunctional molecules, tumor selectivity, protein degradation, HLD-0915, Johnson & Johnson, Halda Therapeutics

Following the wave of "induced proximity" drug development led by Proteolysis Targeting Chimeras (PROTACs), a novel type of bifunctional molecule—RIPTAC (Regulated Induced Proximity Targeting Chimera)—has emerged with a unique anti-cancer logic. In 2025, Halda Therapeutics' first RIPTAC molecule, HLD-0915, completed its first patient dosing, marking the technology's transition from the lab to the clinic. In November of the same year, Johnson & Johnson acquired Halda for $3.05 billion, setting a record for the largest transaction in the induced proximity field. Why has RIPTAC garnered such significant industry investment? How does its technological principle fundamentally differ from traditional protein degradation? What are the latest clinical advancements? This article systematically analyzes RIPTAC technology based on the latest literature published from 2025 to 2026.

The core logic of PROTAC technology is to use bifunctional small molecules to simultaneously bind target proteins and E3 ubiquitin ligases, inducing target protein degradation via the ubiquitin-proteasome system. RIPTAC also employs heterobifunctional molecule design—one end binds the target protein, while the other binds an effector protein—but its ultimate goal is functional inactivation rather than degradation.

The fundamental difference lies in the choice of the effector end. PROTAC's effector end is an E3 ubiquitin ligase, which "tags" the target protein with ubiquitin for degradation. RIPTAC's effector end, however, is a "pan-essential effector protein" critical for cell survival. When RIPTAC forcibly brings the tumor-specific target protein and this effector protein into close proximity, forming a stable ternary complex, the effector protein's normal function is "hijacked" and inactivated. Since the effector protein is essential for cell survival, its functional loss directly leads to cell death.

The key to this mechanism is tumor selectivity: RIPTAC forms ternary complexes only in cells that co-express the target and effector proteins. In normal cells, where the target protein is absent or minimally expressed, ternary complexes cannot form, leaving the effector protein's function unaffected.

As a heterobifunctional small molecule, RIPTAC consists of three parts: a target protein-binding ligand, an effector protein-binding ligand, and a chemical linker connecting the two. The design challenge lies in achieving highly selective ternary complex formation rather than simple binary binding.

A 2025 Yale University doctoral dissertation systematically studied RIPTAC's design principles. Researchers designed RIPTAC molecules targeting ALK and CDK, finding that while ternary complexes formed, off-target complexes led to insufficient selectivity. Subsequently, using BCL6 (an oncogenic driver protein) as the target and BRD4 (a pan-essential protein) as the effector, they constructed the RIPTAC molecule HLDA-6623. Studies revealed that its cytotoxicity was mediated not through transcriptional reprogramming but directly via RIPTAC's unique ternary complex formation mechanism.

For target selection, RIPTAC requires the target protein to be highly expressed in tumor cells, while the effector protein must be essential for all cell survival. This "tumor-high target × universally essential effector" combination offers a new approach to targeting traditionally "undruggable" targets—such as mutant p53.

At the 2025 AACR Annual Meeting, the Lupey-Green team reported an orally bioavailable RIPTAC molecule targeting the p53-Y220C mutation. p53 is a tumor suppressor gene mutated in over 50% of human cancers, with the Y220C mutation being a structurally unique missense mutation that reduces DNA-binding capacity and impairs tumor-suppressive function.

This RIPTAC molecule binds mutant p53-Y220C at one end and a cell survival-critical essential protein at the other, inducing ternary complex formation. Its mechanism is dual: it "hijacks" mutant p53 to disable its function while blocking the essential protein's activity to directly trigger tumor cell death. This approach differs from previous pharmacological chaperone strategies aiming to "repair" mutant p53 back to wild-type function—the latter often fails to induce sufficient or sustained tumor cell death in monotherapy.

HLD-0915 is the first RIPTAC molecule to enter clinical trials, targeting the androgen receptor (AR) in prostate cancer. In 2025, Halda Therapeutics initiated a Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC). Preclinical models showed tumor regression and a favorable therapeutic index for HLD-0915, even in resistant settings. Phase I data demonstrated good tolerability and encouraging anti-tumor activity in heavily pretreated mCRPC patients. Notably, HLD-0915 showed positive therapeutic effects across AR mutations, splice variants, amplifications, and genomic heterogeneity.

Johnson & Johnson's $3.05 billion acquisition of Halda was a key industry endorsement for RIPTAC technology. In November 2025, Johnson & Johnson acquired Halda Therapeutics for $3.05 billion in cash. The company stated that the RIPTAC platform could overcome resistance mechanisms in cancer therapy, and beyond HLD-0915, it gained early-stage candidates for breast cancer, lung cancer, and other solid tumors.

Other industry developments include Parabilis Medicines advancing its Helicon platform for protein degraders, RIPTACs, and radiopharmaceuticals. In early 2026, an academic presentation framed molecular glues as a precursor to RIPTAC, highlighting the evolution from "serendipitous discovery" to "induced proximity" design principles.

RIPTAC's uniqueness lies in its independence from the proteasome degradation system, avoiding limitations like target protein degradation efficiency or E3 ligase tissue distribution. Its "hijacking" mechanism may also overcome resistance issues faced by PROTACs—for example, when target protein mutations reduce degrader binding, RIPTAC can still exert cytotoxic effects via effector protein inactivation.

RIPTAC development still faces multiple challenges. First, selective ternary complex formation is the core hurdle—ensuring RIPTAC forms functional complexes only in tumor cells while avoiding off-target effects in normal cells. Second, effector protein selection must balance "essentiality" and "druggability"—overly broad effectors may cause unacceptable toxicity, while overly specific ones may limit therapeutic scope. Additionally, as heterobifunctional molecules, RIPTACs require ongoing optimization for oral bioavailability, metabolic stability, and synthetic scalability.

Looking ahead, RIPTAC technology may expand in these directions: targeting more "undruggable" tumor-specific targets (e.g., KRAS mutants, MYC); developing bifunctional molecules for solid tumors; and exploring combinations with immunotherapies, ADCs, and other modalities.

RIPTAC represents another leap in the "induced proximity" drug development paradigm—from "degrading harmful proteins" to "hijacking essential proteins to kill tumor cells." With HLD-0915's accumulating clinical data and Johnson & Johnson's massive investment, this technology is transitioning from proof-of-concept to clinical validation. For the biopharma industry, RIPTAC not only expands druggable protein space but also offers a novel therapeutic logic beyond traditional inhibition and degradation.